Omnicell Q3 revenue $348M (+17% YoY); GAAP EPS $0.37; guides Q4 revenue $285M-$295M

OMNICELL, INC.

2022-Q3 EPS reported $0.73 revenue$998,273,000

GAAP net income $17M ($0.37/diluted share) vs $29M ($0.61) in Q3 2021.
Non-GAAP net income $45M ($1.00/diluted share) vs $50M ($1.08) YoY.
FY 2022 revenue guidance lowered to $1.284B-$1.294B; non-GAAP EPS $2.73-$2.83.
Q4 revenue forecast $285M-$295M, down sharply from Q3's $348M.
Cites health system capital freezes and labor shortages as headwinds; plans cost structure adjustments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OMNICELL, INC. reported third quarter ended September 30, 2022 results: revenue $348 million, net income $17 million, or $0.37 per diluted share, EPS $1.00 per diluted share. Guidance lowered.

Period: third quarter ended September 30, 2022
Revenue: $348 million
Net income: $17 million, or $0.37 per diluted share
EPS: $1.00 per diluted share
Guidance: lowered
Result: reported results

Exact text from the filing

Omnicell Announces Financial Results for Third Quarter 2022 GAAP and non-GAAP revenues of $348 million GAAP net income per diluted share of $0.37 Non-GAAP net income per diluted share of $1.00

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OMNICELL, INC. filing history →

Source: SEC EDGAR

accession 0000926326-22-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.